We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Viatris to Buy Pacira for $1.65B to Expand Non-Opioid Pain Portfolio
Read MoreHide Full Article
Key Takeaways
VTRS to buy PCRX for $1.65B in cash at $36.50 per share, with the deal expected to close by the end of 2026.
Exparel and Zilretta, which generated $350.5 million in H1 2026 sales, will be added to VTRS' pain portfolio.
Pacira's PCRX-201 gene therapy candidate will add a mid-stage knee osteoarthritis treatment to VTRS' pipeline.
Viatris (VTRS - Free Report) has entered into a definitive agreement to acquire Pacira BioSciences (PCRX - Free Report) for $1.65 billion in cash. The deal is expected to expand VTRS’ innovative medicines portfolio and strengthen its position in non-opioid pain management. PCRX stock rallied 44.4% after the announcement as investors responded favorably to the acquisition offer. The transaction will bring two marketed pain therapies and a clinical-stage gene therapy candidate into Viatris’ business, broadening its presence in specialty pain care with alternatives to opioid-based relief.
Under the agreement, Viatris will acquire all outstanding Pacira common shares for $36.50 per share in cash, representing an aggregate equity value of $1.65 billion. Viatris plans to commence a tender offer and subsequently acquire any remaining shares through a second-step merger at the same price. Both companies’ boards have unanimously approved the transaction, and completion remains subject to customary closing conditions, including the tender of a majority of Pacira’s outstanding shares and regulatory clearance.
The acquisition is expected to close by the end of 2026. Viatris intends to finance the acquisition primarily through excess cash, with the remainder funded by short-term borrowings, and expects minimal impact on its gross leverage ratio. The deal is also expected to be immediately accretive to Viatris’ financial guidance metrics. Pacira generated approximately $746 million in revenues and $177 million in adjusted EBITDA in the 12 months ended June 30, 2026.
The Rationale Behind VTRS' Impending Acquisition of PCRX
The acquisition adds two established, patent-protected, high-margin medicines to Viatris’ commercial portfolio — Exparel (bupivacaine liposome injectable suspension) and Zilretta (triamcinolone acetonide extended-release injectable suspension). Exparel is indicated for postsurgical local analgesia in patients aged six years and older and for postsurgical regional analgesia through specified nerve blocks in adults. Pacira reported $291.1 million in Exparel net product sales during the first half of 2026. The product gives Viatris an established commercial presence in post-surgical pain management.
Year to date, VTRS’ shares have appreciated 40%, while PCRX shares have rallied 40.6% compared with the industry’s 3.4% growth.
Image Source: Zacks Investment Research
Zilretta is an extended-release intra-articular injection indicated for managing osteoarthritis-related knee pain. It generated $59.4 million in net product sales during the first half of 2026. Together, Exparel and Zilretta generated $350.5 million in first-half product sales, providing Viatris with a substantial marketed revenue base. Viatris plans to leverage its intellectual property expertise and product life-cycle management capabilities to maximize the long-term value of the Pacira portfolio and sustain meaningful sales after competition emerges. The company also expects to expand Exparel and Zilretta into select international markets through its global infrastructure.
Beyond the marketed products, Pacira brings U.S. commercial, market access and medical affairs capabilities, along with global research and development resources that complement Viatris’ existing operations. The acquisition is also expected to create synergies with Viatris’ fast-acting meloxicam opportunity, potentially broadening its non-opioid pain management portfolio across multiple clinical settings. These capabilities could strengthen Viatris’ innovative medicines business and support the commercialization of specialty therapies.
The deal also expands Viatris’ development pipeline with PCRX-201 (enekinragene inzadenovec), Pacira’s most advanced clinical candidate. This locally administered gene therapy is in mid-stage development for osteoarthritis of the knee and represents a potential opportunity for Viatris to broaden its presence in musculoskeletal pain. Enrollment is underway in Part B of the phase II ASCEND study, while top-line data from Part A are expected by the end of 2026. The addition gives Viatris another development-stage asset alongside its marketed pain medicines, with potential for longer-term growth.
For Pacira, the deal grants access to Viatris’ global scale, resources and commercial infrastructure, which could help expand the reach of its therapies into select international markets and expedite pipeline progress.
Over the past 60 days, loss per share estimates for Amarin have narrowed from 65 cents to 39 cents for 2026. Over the same period, estimates for 2027 loss per share have narrowed from 51 cents to 50 cents. AMRN’s shares have lost 14.1% year to date.
Amarin’s earnings beat estimates in three of the trailing four quarters and missed in the remaining one, the average surprise being 62.27%.
Over the past 60 days, earnings per share estimates for Alnylam Pharmaceuticals have decreased from $8.65 to $8.63 for 2026. Over the same period, estimates for 2027 earnings per share have narrowed from $12.13 to $12.04. ALNY’s shares have plunged 43.5% year to date.
Alnylam Pharmaceuticals’ earnings beat estimates in three of the trailing four quarters and missed in the remaining one, the average surprise being 27.58%.
View the Zacks #1 Rank List
Image: Bigstock
Viatris to Buy Pacira for $1.65B to Expand Non-Opioid Pain Portfolio
Key Takeaways
Viatris (VTRS - Free Report) has entered into a definitive agreement to acquire Pacira BioSciences (PCRX - Free Report) for $1.65 billion in cash. The deal is expected to expand VTRS’ innovative medicines portfolio and strengthen its position in non-opioid pain management. PCRX stock rallied 44.4% after the announcement as investors responded favorably to the acquisition offer. The transaction will bring two marketed pain therapies and a clinical-stage gene therapy candidate into Viatris’ business, broadening its presence in specialty pain care with alternatives to opioid-based relief.
Under the agreement, Viatris will acquire all outstanding Pacira common shares for $36.50 per share in cash, representing an aggregate equity value of $1.65 billion. Viatris plans to commence a tender offer and subsequently acquire any remaining shares through a second-step merger at the same price. Both companies’ boards have unanimously approved the transaction, and completion remains subject to customary closing conditions, including the tender of a majority of Pacira’s outstanding shares and regulatory clearance.
The acquisition is expected to close by the end of 2026. Viatris intends to finance the acquisition primarily through excess cash, with the remainder funded by short-term borrowings, and expects minimal impact on its gross leverage ratio. The deal is also expected to be immediately accretive to Viatris’ financial guidance metrics. Pacira generated approximately $746 million in revenues and $177 million in adjusted EBITDA in the 12 months ended June 30, 2026.
The Rationale Behind VTRS' Impending Acquisition of PCRX
The acquisition adds two established, patent-protected, high-margin medicines to Viatris’ commercial portfolio — Exparel (bupivacaine liposome injectable suspension) and Zilretta (triamcinolone acetonide extended-release injectable suspension). Exparel is indicated for postsurgical local analgesia in patients aged six years and older and for postsurgical regional analgesia through specified nerve blocks in adults. Pacira reported $291.1 million in Exparel net product sales during the first half of 2026. The product gives Viatris an established commercial presence in post-surgical pain management.
Year to date, VTRS’ shares have appreciated 40%, while PCRX shares have rallied 40.6% compared with the industry’s 3.4% growth.
Image Source: Zacks Investment Research
Zilretta is an extended-release intra-articular injection indicated for managing osteoarthritis-related knee pain. It generated $59.4 million in net product sales during the first half of 2026. Together, Exparel and Zilretta generated $350.5 million in first-half product sales, providing Viatris with a substantial marketed revenue base. Viatris plans to leverage its intellectual property expertise and product life-cycle management capabilities to maximize the long-term value of the Pacira portfolio and sustain meaningful sales after competition emerges. The company also expects to expand Exparel and Zilretta into select international markets through its global infrastructure.
Beyond the marketed products, Pacira brings U.S. commercial, market access and medical affairs capabilities, along with global research and development resources that complement Viatris’ existing operations. The acquisition is also expected to create synergies with Viatris’ fast-acting meloxicam opportunity, potentially broadening its non-opioid pain management portfolio across multiple clinical settings. These capabilities could strengthen Viatris’ innovative medicines business and support the commercialization of specialty therapies.
The deal also expands Viatris’ development pipeline with PCRX-201 (enekinragene inzadenovec), Pacira’s most advanced clinical candidate. This locally administered gene therapy is in mid-stage development for osteoarthritis of the knee and represents a potential opportunity for Viatris to broaden its presence in musculoskeletal pain. Enrollment is underway in Part B of the phase II ASCEND study, while top-line data from Part A are expected by the end of 2026. The addition gives Viatris another development-stage asset alongside its marketed pain medicines, with potential for longer-term growth.
For Pacira, the deal grants access to Viatris’ global scale, resources and commercial infrastructure, which could help expand the reach of its therapies into select international markets and expedite pipeline progress.
Viatris Inc. Price and Consensus
Viatris Inc. price-consensus-chart | Viatris Inc. Quote
VTRS’ Zacks Rank & Other Stocks to Consider
Viatris currently carries a Zacks Rank #2 (Buy).
Some other top-ranked stocks in the biotech sector are Amarin (AMRN - Free Report) and Alnylam Pharmaceuticals (ALNY - Free Report) , each currently sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Over the past 60 days, loss per share estimates for Amarin have narrowed from 65 cents to 39 cents for 2026. Over the same period, estimates for 2027 loss per share have narrowed from 51 cents to 50 cents. AMRN’s shares have lost 14.1% year to date.
Amarin’s earnings beat estimates in three of the trailing four quarters and missed in the remaining one, the average surprise being 62.27%.
Over the past 60 days, earnings per share estimates for Alnylam Pharmaceuticals have decreased from $8.65 to $8.63 for 2026. Over the same period, estimates for 2027 earnings per share have narrowed from $12.13 to $12.04. ALNY’s shares have plunged 43.5% year to date.
Alnylam Pharmaceuticals’ earnings beat estimates in three of the trailing four quarters and missed in the remaining one, the average surprise being 27.58%.